妇科肿瘤学工作组：局部晚期和转移性乳腺癌患者的诊断和治疗建议：2024年更新
Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2024.
作者信息
Thill Marc, Janni Wolfgang, Albert Ute-Susann, Banys-Paluchowski Maggie, Bauerfeind Ingo, Blohmer Jens, Budach Wilfried, Dall Peter, Ditsch Nina, Fallenberg Eva Maria, Fasching Peter A, Fehm Tanja, Friedrich Michael, Gerber Bernd, Gluz Oleg, Harbeck Nadia, Hartkopf Andreas, Heil Jörg, Huober Jens, Jackisch Christian, Kolberg-Liedtke Cornelia, Kreipe Hans-Heinrich, Krug David, Kühn Thorsten, Kümmel Sherko, Loibl Sibylle, Lüftner Diana, Lux Michael Patrick, Maass Nicolai, Mundhenke Christoph, Reimer Toralf, Rhiem Kerstin, Rody Achim, Schmidt Marcus, Schneeweiss Andreas, Schütz Florian, Sinn Hans-Peter, Solbach Christine, Solomayer Erich-Franz, Stickeler Elmar, Thomssen Christoph, Untch Michael, Witzel Isabell, Wöckel Achim, Würstlein Rachel, Müller Volkmar, Park-Simon Tjoung-Won
机构信息
Klinik für Gynäkologie und Gynäkologische Onkologie, Agaplesion Markus Krankenhaus, Frankfurt, Germany.
Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Ulm, Ulm, Germany.
出版信息
Breast Care (Basel). 2024 Jun;19(3):183-191. doi: 10.1159/000538753. Epub 2024 Apr 10.
Abstract
The Breast Committee of the Arbeitsgemeinschaft Gynäkologische Onkologie (German Gynecological Oncology Group, AGO) presents the 2024 update of the evidence-based recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer.
摘要
德国妇科肿瘤学会（AGO）乳腺委员会发布了2024年局部晚期和转移性乳腺癌患者诊断与治疗的循证推荐更新版。
相似文献
1
Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2024.妇科肿瘤学工作组：局部晚期和转移性乳腺癌患者的诊断和治疗建议：2024年更新
Breast Care (Basel). 2024 Jun;19(3):183-191. doi: 10.1159/000538753. Epub 2024 Apr 10.
2
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022.AGO关于局部晚期和转移性乳腺癌患者诊断与治疗的建议：2022年更新版
Breast Care (Basel). 2022 Aug;17(4):421-429. doi: 10.1159/000524789. Epub 2022 May 2.
3
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2025.AGO关于局部晚期和转移性乳腺癌患者诊断与治疗的建议：2025年更新版
Breast Care (Basel). 2025 Mar 8:1-12. doi: 10.1159/000545018.
4
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2023.AGO关于局部晚期和转移性乳腺癌患者诊断与治疗的建议：2023年更新版
Breast Care (Basel). 2023 Aug;18(4):306-315. doi: 10.1159/000531579. Epub 2023 Jun 16.
5
Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2024.妇科肿瘤协作组《早期乳腺癌患者诊断与治疗建议：2024年更新》
Breast Care (Basel). 2024 Jun;19(3):165-182. doi: 10.1159/000538596. Epub 2024 Apr 18.
6
Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2023.妇科肿瘤学工作组：早期乳腺癌患者的诊断和治疗建议：2023年更新
Breast Care (Basel). 2023 Aug;18(4):289-305. doi: 10.1159/000531578. Epub 2023 Jun 16.
7
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019.AGO关于局部晚期和转移性乳腺癌患者诊断与治疗的建议：2019年更新版
Breast Care (Basel). 2019 Aug;14(4):247-255. doi: 10.1159/000500999. Epub 2019 Jul 30.
8
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2025.AGO早期乳腺癌患者诊断与治疗建议：2025年更新版
Breast Care (Basel). 2025 Mar 8:1-19. doi: 10.1159/000545019.
9
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022.AGO早期乳腺癌患者诊断与治疗建议：2022年更新版
Breast Care (Basel). 2022 Aug;17(4):403-420. doi: 10.1159/000524879. Epub 2022 May 5.
10
ABC7 Consensus: Assessment by a German Group of Experts.ABC7共识：德国专家小组的评估
Breast Care (Basel). 2024 Apr;19(2):116-128. doi: 10.1159/000535997. Epub 2024 Jan 24.
引用本文的文献
1
Update Breast Cancer 2024 Part 3 - Patients with Advanced Stage Breast Cancer.《2024年乳腺癌最新进展 第3部分 - 晚期乳腺癌患者》
Geburtshilfe Frauenheilkd. 2025 May 15;85(5):507-519. doi: 10.1055/a-2515-2366. eCollection 2025 May.
2
Prognostic Factors in Therapy Regimes of Breast Cancer Patients with Brain Metastases: A Retrospective Monocentric Analysis.乳腺癌脑转移患者治疗方案中的预后因素：一项回顾性单中心分析
Cancers (Basel). 2025 Jan 15;17(2):261. doi: 10.3390/cancers17020261.
本文引用的文献
1
Intrathecal Therapy Options for Meningeal Carcinomatosis.脑膜癌病的鞘内治疗选择
Geburtshilfe Frauenheilkd. 2023 Nov 8;84(1):59-67. doi: 10.1055/a-2185-0457. eCollection 2024 Jan.
2
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2023.AGO关于局部晚期和转移性乳腺癌患者诊断与治疗的建议：2023年更新版
Breast Care (Basel). 2023 Aug;18(4):306-315. doi: 10.1159/000531579. Epub 2023 Jun 16.
3
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial.在激素受体阳性和人表皮生长因子受体 2 阴性转移性乳腺癌（TROPiCS-02）中 sacituzumab govitecan 的总生存期：一项随机、开放标签、多中心、III 期临床试验。
Lancet. 2023 Oct 21;402(10411):1423-1433. doi: 10.1016/S0140-6736(23)01245-X. Epub 2023 Aug 23.
4
Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer.HER2DX 与 HER2 阳性乳腺癌的病理完全缓解和生存结局的关联。
Ann Oncol. 2023 Sep;34(9):783-795. doi: 10.1016/j.annonc.2023.05.012. Epub 2023 Jun 9.
5
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.卡培他滨联合卡培他滨对比安慰剂联合氟维司群治疗激素受体阳性、人表皮生长因子受体 2 阴性晚期乳腺癌的随机、双盲、III 期临床研究
N Engl J Med. 2023 Jun 1;388(22):2058-2070. doi: 10.1056/NEJMoa2214131.
6
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial.激素受体阳性、人表皮生长因子受体 2 阴性转移性乳腺癌 CDK4/6 抑制进展后内分泌治疗联合或不联合瑞博西利的随机 II 期试验：MAINTAIN 试验。
J Clin Oncol. 2023 Aug 20;41(24):4004-4013. doi: 10.1200/JCO.22.02392. Epub 2023 May 19.
7
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.曲妥珠单抗-德鲁替康对比曲妥珠单抗-美坦新用于治疗 HER2 阳性转移性乳腺癌患者：来自随机、开放标签、III 期 DESTINY-Breast03 研究的更新结果。
Lancet. 2023 Jan 14;401(10371):105-117. doi: 10.1016/S0140-6736(22)02420-5. Epub 2022 Dec 7.
8
Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial.图卡替尼对比安慰剂，均联合曲妥珠单抗和卡培他滨，用于治疗先前接受过治疗的 ERBB2（HER2）阳性转移性乳腺癌且伴有脑转移的患者：HER2CLIMB 随机临床试验的更新探索性分析。
JAMA Oncol. 2023 Feb 1;9(2):197-205. doi: 10.1001/jamaoncol.2022.5610.
9
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.Elacestrant（口服选择性雌激素受体降解剂）对比标准内分泌治疗用于雌激素受体阳性、人表皮生长因子受体 2 阴性的晚期乳腺癌：来自随机 III 期 EMERALD 试验的结果。
J Clin Oncol. 2022 Oct 1;40(28):3246-3256. doi: 10.1200/JCO.22.00338. Epub 2022 May 18.
10
Treatment response and 5-year distant metastasis-free survival outcome in breast cancer patients after the use of MammaPrint and BluePrint to guide preoperative systemic treatment decisions.在使用 MammaPrint 和 BluePrint 指导术前全身治疗决策后，乳腺癌患者的治疗反应和 5 年远处无转移生存结果。
Eur J Cancer. 2022 May;167:92-102. doi: 10.1016/j.ejca.2022.03.003. Epub 2022 Apr 11.
Zotero 插件